Last reviewed · How we verify
Placebo pill imitating pentoxiphylline
Placebo pill imitating pentoxiphylline is a Small molecule drug developed by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. It is currently in Phase 3 development for Control arm in Phase 3 clinical trials (specific indication depends on the pentoxifylline trial being conducted). Also known as: Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-, inflammatory and appetite-stimulating pill while subjects undergo thrice, weekly hemodialysis and during the following non-dialysis day (6 days per week).
This is a placebo pill designed to mimic pentoxifylline in appearance for use as a control in clinical trials.
This is a placebo pill designed to mimic pentoxifylline in appearance for use as a control in clinical trials. Used for Control arm in Phase 3 clinical trials (specific indication depends on the pentoxifylline trial being conducted).
At a glance
| Generic name | Placebo pill imitating pentoxiphylline |
|---|---|
| Also known as | Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-, inflammatory and appetite-stimulating pill while subjects undergo thrice, weekly hemodialysis and during the following non-dialysis day (6 days per week) |
| Sponsor | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation contains no active pharmaceutical ingredient and produces no pharmacological effect. It is used in Phase 3 trials to serve as a control arm against pentoxifylline, which is a methylxanthine derivative that improves blood flow by reducing blood viscosity and increasing red blood cell deformability. The placebo allows researchers to isolate the true therapeutic effect of pentoxifylline from placebo response.
Approved indications
- Control arm in Phase 3 clinical trials (specific indication depends on the pentoxifylline trial being conducted)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo pill imitating pentoxiphylline CI brief — competitive landscape report
- Placebo pill imitating pentoxiphylline updates RSS · CI watch RSS
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center portfolio CI
Frequently asked questions about Placebo pill imitating pentoxiphylline
What is Placebo pill imitating pentoxiphylline?
How does Placebo pill imitating pentoxiphylline work?
What is Placebo pill imitating pentoxiphylline used for?
Who makes Placebo pill imitating pentoxiphylline?
Is Placebo pill imitating pentoxiphylline also known as anything else?
What development phase is Placebo pill imitating pentoxiphylline in?
Related
- Manufacturer: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — full pipeline
- Indication: Drugs for Control arm in Phase 3 clinical trials (specific indication depends on the pentoxifylline trial being conducted)
- Also known as: Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-, inflammatory and appetite-stimulating pill while subjects undergo thrice, weekly hemodialysis and during the following non-dialysis day (6 days per week)
- Compare: Placebo pill imitating pentoxiphylline vs similar drugs
- Pricing: Placebo pill imitating pentoxiphylline cost, discount & access